Clinical Trials Browser

Phase 2/3 × Interventional × Squamous Cell Carcinoma of Head and Neck × Clear all

NCT01810913 2026-04-17

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Phase 2/3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07535567 2026-04-17

NimoBenSeq

Phase 2/3 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04534205 2026-04-15

AHEAD-MERIT

Phase 2/3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT03952585 2026-04-13

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

Phase 2/3 Active not recruiting

384 enrolled 22 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Oropharyngeal Neoplasms

NCT05063552 2026-04-13

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Phase 2/3 Active not recruiting

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04333537 2026-04-03

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

Phase 2/3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Mouth Neoplasms

NCT06295731 2026-03-31

HexAgon-HN

Phase 2/3 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06788990 2026-03-23

FORTIFI-HN01

Phase 2/3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Camurati-Engelmann Syndrome, Head and Neck Neoplasms, Laryngeal Diseases

NCT06030440 2026-03-13

DIREKHT2

Phase 2/3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT03258554 2026-02-06

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Phase 2/3 Completed

196 enrolled 31 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06082167 2025-08-17

STELLAR-305

Phase 2/3 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06513884 2025-06-22

A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer

Phase 2/3 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT05893888 2025-06-15

Safety and Efficacy Study of PRV111 and PRV211 in Subjects With Oral Squamous Cell Carcinoma

Phase 2/3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06719479 2024-12-05

A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).

Phase 2/3 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT02923258 2024-06-20

Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer

Phase 2/3 Completed

Squamous Cell Carcinoma of Head and Neck

NCT05125055 2023-11-22

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Phase 2/3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06016400 2023-08-29

Using Vitamin D to Reduce Oral Mucosal Inflammation in Chemotherapy Patients With Oral Squamous Cell Carcinoma

Phase 2/3 Unknown

Squamous Cell Carcinoma of Head and Neck, Stomatitis

NCT04969861 2023-01-12

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

Phase 2/3 Terminated

1 enrolled 6 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04129320 2022-02-08

Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck

Phase 2/3 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Neoplasms

NCT01542931 2017-08-21

TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma

Phase 2/3 Completed

Squamous Cell Carcinoma of Head and Neck

NCT00002533 2016-12-15

Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer

Phase 2/3 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Infections, Esthesioneuroblastoma, Olfactory

NCT00412776 2015-12-23

Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer

Phase 2/3 Terminated

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms, Squamous Cell

NCT00162708 2005-09-13

Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC

Phase 2/3 Completed

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms